A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Kong, Mei, Ph.D. Bookmark and Share

Laboratory of Mei Kong, Ph.D.

Signal transduction and Cancer Metabolism
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation.  Glucose and glutamine are two main nutrients whose uptake is directly controlled by signal transduction and are essential for tumor cell survival and proliferation.  Altered glucose metabolism in cancer cells is termed the Warburg effect, which describes the propensity of most cancer cells to take up glucose avidly and convert it primarily to lactate, despite available oxygen.   In addition to glucose, glutamine is another essential nutrient whose uptake is directly controlled by oncogenes, and it is critical for cancer cell survival and proliferation.  During tumor growth, increased uptake of nutrients and rapid accumulation of cells can outstrip the supply of essential nutrients, including glucose and glutamine.  How tumor cells survive these temporary periods of nutrient deprivation is unclear, but is necessary for tumorigenesis to persist.  The major goal of our laboratory is to delineate the strategies used by tumor cells to survive periods of nutrient deprivation and then to develop novel therapies targeting nutrient-sensing pathways of neoplastic cells.  Exciting progress has been made over the past 20 years in elucidating how cancer cells survive glucose deprivation via mTOR, AMPK and p53 pathway.  In contrast, less is known about the signal transduction pathways that regulate tumor cells’ survival during glutamine deprivation, in spite of the evidence that has been noticed for many years, that glutamine fell from a high level in normal tissue to a level not detectable in different solid tumors.  Thus, identifying the critical regulators that control tumor cell survival during glutamine deprivation may lead to the development of novel and safer cancer therapies.  We recently discovered that protein phosphatase 2A (PP2A)-associated protein, α4, plays a conserved role in glutamine sensing. α4 promotes assembly of an adaptive PP2A complex containing the B55α regulatory subunit via providing the catalytic subunit upon glutamine deprivation. Moreover, B55α is specifically induced upon glutamine deprivation in a ROS-dependent manner to activate p53 and promote cell survival. B55α activates p53 through direct interaction and dephosphorylation of EDD, a negative regulator of p53. Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo. In future work, we will focus on understanding how p53 activation regulates tumor cell survival under glutamine deprivation, and identify critical p53 targets that contribute to cancer cell survival under glutamine limitation.  Our long-term goal is to identify the signals that allow communication between oncogenic pathways and tumor cell metabolism and develop novel therapeutics targeting metabolic differences between rapidly-proliferating cancer cells and normal cells.
 
Regulation of Protein Phosphatase 2A Complexes
Reversible protein phosphorylation is the major regulatory mechanism used by cells to respond to environmental and nutritional stresses.  Aberrant regulation of this activity leads to dysregulated cellular behavior and disease phenotypes, including many forms of cancer. Although we know much about how protein kinases function in specific signaling governed by phosphorylation, whether protein phosphatases are also regulated and actively function in the process to counteract kinase function has not been established. Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many signaling pathways. Unlike kinases, serine/threonine phosphatases are promiscuously active and their specificity is governed largely by associated proteins. Thus, the specificity of PP2A is conferred by assembly of a trimeric complex including a catalytic C subunit, a scaffolding A subunit, and one of the sixteen regulatory B subunits. In addition to interacting with conventional A and B subunits, the C subunit reportedly forms two other distinct complexes with proteins designated α4 (Tap42 in yeast) and Tiprl (Tip41 in yeast).  Our laboratory also interested in characterizing molecular mechanisms underlying the response of PP2A complexes to stress signals.
 
For more information on Dr. Kong, please click here.

Mei Kong, Ph.D. Lab Members

Lab Members
 
Jenny Davies, Ph.D
Postdoctoral Fellow
626-256-4673, ext.30158
jedavies@coh.org
 
Min Pan, Ph.D.
Postdoctoral Fellow
626-256-4673 ext.  30158
minoan@coh.org

Michael Reid, B.S.
Graduate Student
626-256-4673, ext. 30158
mrieda@coh.org
 
Kimberly Rosales, Ph.D.
Postdoctoral Fellow
626-256-4673, ext. 30158
krosales@coh.org
 
Xazmin Lowman, Ph.D
Postdoctoral Fellow
626-256-4673, ext. 64450
 

Kong, Mei, Ph.D.

Laboratory of Mei Kong, Ph.D.

Signal transduction and Cancer Metabolism
Tumor cells often display fundamental changes in metabolism and increase their uptake of nutrients to meet the increased bioenergetic demands of proliferation.  Glucose and glutamine are two main nutrients whose uptake is directly controlled by signal transduction and are essential for tumor cell survival and proliferation.  Altered glucose metabolism in cancer cells is termed the Warburg effect, which describes the propensity of most cancer cells to take up glucose avidly and convert it primarily to lactate, despite available oxygen.   In addition to glucose, glutamine is another essential nutrient whose uptake is directly controlled by oncogenes, and it is critical for cancer cell survival and proliferation.  During tumor growth, increased uptake of nutrients and rapid accumulation of cells can outstrip the supply of essential nutrients, including glucose and glutamine.  How tumor cells survive these temporary periods of nutrient deprivation is unclear, but is necessary for tumorigenesis to persist.  The major goal of our laboratory is to delineate the strategies used by tumor cells to survive periods of nutrient deprivation and then to develop novel therapies targeting nutrient-sensing pathways of neoplastic cells.  Exciting progress has been made over the past 20 years in elucidating how cancer cells survive glucose deprivation via mTOR, AMPK and p53 pathway.  In contrast, less is known about the signal transduction pathways that regulate tumor cells’ survival during glutamine deprivation, in spite of the evidence that has been noticed for many years, that glutamine fell from a high level in normal tissue to a level not detectable in different solid tumors.  Thus, identifying the critical regulators that control tumor cell survival during glutamine deprivation may lead to the development of novel and safer cancer therapies.  We recently discovered that protein phosphatase 2A (PP2A)-associated protein, α4, plays a conserved role in glutamine sensing. α4 promotes assembly of an adaptive PP2A complex containing the B55α regulatory subunit via providing the catalytic subunit upon glutamine deprivation. Moreover, B55α is specifically induced upon glutamine deprivation in a ROS-dependent manner to activate p53 and promote cell survival. B55α activates p53 through direct interaction and dephosphorylation of EDD, a negative regulator of p53. Importantly, the B55α-EDD-p53 pathway is essential for cancer cell survival and tumor growth under low glutamine conditions in vitro and in vivo. In future work, we will focus on understanding how p53 activation regulates tumor cell survival under glutamine deprivation, and identify critical p53 targets that contribute to cancer cell survival under glutamine limitation.  Our long-term goal is to identify the signals that allow communication between oncogenic pathways and tumor cell metabolism and develop novel therapeutics targeting metabolic differences between rapidly-proliferating cancer cells and normal cells.
 
Regulation of Protein Phosphatase 2A Complexes
Reversible protein phosphorylation is the major regulatory mechanism used by cells to respond to environmental and nutritional stresses.  Aberrant regulation of this activity leads to dysregulated cellular behavior and disease phenotypes, including many forms of cancer. Although we know much about how protein kinases function in specific signaling governed by phosphorylation, whether protein phosphatases are also regulated and actively function in the process to counteract kinase function has not been established. Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many signaling pathways. Unlike kinases, serine/threonine phosphatases are promiscuously active and their specificity is governed largely by associated proteins. Thus, the specificity of PP2A is conferred by assembly of a trimeric complex including a catalytic C subunit, a scaffolding A subunit, and one of the sixteen regulatory B subunits. In addition to interacting with conventional A and B subunits, the C subunit reportedly forms two other distinct complexes with proteins designated α4 (Tap42 in yeast) and Tiprl (Tip41 in yeast).  Our laboratory also interested in characterizing molecular mechanisms underlying the response of PP2A complexes to stress signals.
 
For more information on Dr. Kong, please click here.

Laboratory Members

Mei Kong, Ph.D. Lab Members

Lab Members
 
Jenny Davies, Ph.D
Postdoctoral Fellow
626-256-4673, ext.30158
jedavies@coh.org
 
Min Pan, Ph.D.
Postdoctoral Fellow
626-256-4673 ext.  30158
minoan@coh.org

Michael Reid, B.S.
Graduate Student
626-256-4673, ext. 30158
mrieda@coh.org
 
Kimberly Rosales, Ph.D.
Postdoctoral Fellow
626-256-4673, ext. 30158
krosales@coh.org
 
Xazmin Lowman, Ph.D
Postdoctoral Fellow
626-256-4673, ext. 64450
 
Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
NEWS & UPDATES
  • Although chemotherapy can be effective in treating cancer, it can also exact a heavy toll on a patient’s health. One impressive alternative researchers have found is in the form of a vaccine. A type of immunotherapy, one part of the vaccine primes the body to react strongly against a tumor; the second part dire...
  • The breast cancer statistic is attention-getting: One in eight women will be diagnosed with breast cancer during her lifetime. That doesn’t mean that, if you’re one of eight women at a dinner table, one of you is fated to have breast cancer (read more on that breast cancer statistic), but it does mean that the ...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. In his first post, ...
  • Advanced age tops the list among breast cancer risk factor for women. Not far behind is family history and genetics. Two City of Hope researchers delving deep into these issues recently received important grants to advance their studies. Arti Hurria, M.D., director of the Cancer and Aging Research Program, and ...
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...
  • All women are at some risk of developing the disease in their lifetimes, but breast cancer, like other cancers, has a disproportionate effect on minorities. Although white women have the highest incidence of breast cancer, African-American women have the highest breast cancer death rates of all racial and ethni...
  • First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worl...
  • Screening for breast cancer has dramatically increased the number of cancers found before they cause symptoms – catching the disease when it is most treatable and curable. Mammograms, however, are not infallible. It’s important to conduct self-exams, and know the signs and symptoms that should be checked by a h...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free.   In his previ...
  • In a single day, former professional triathlete Lisa Birk learned she couldn’t have children and that she had breast cancer. “Where do you go from there?” she asks. For Birk, who swims three miles, runs 10 miles and cycles every day, the answer  ultimately was a decision to take control of her cancer care. Afte...
  • More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools. Today there are nearly 14.5 million cancer survivors in the United States. But in up to 20 percent of cancer patients, the disease ultimately spreads to their brain. Each year, nearly 170,000 new cases of brain ...